FDA Gives Green Light to CardiAMP Heart Cell Therapy for Heart Failure
FDA confirms BioCardia’s CardiAMP Heart Failure II trial may support Premarket Approval for ischemic heart failure.
/ 1653 items
#XY↓
Roth Capital Initiates Coverage on COYA With Buy Rating and Huge ALS Potential
COYA gets Buy rating; ALS drug COYA 302 shows early promise, could double stock if trials succeed, high risk biotech.
Shattuck Labs Stock Gets Bullish Citi Upgrade Before SL-325 Phase 1 Results
Citi upgrades STTK to Buy with $7 price target and 30-day upside watch ahead of SL-325 Phase 1 data in Q2 2026.
Biogen’s Salanersen Wins FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen’s new SMA drug Salanersen shows strong early results, helping kids move better. FDA fast-tracks it with Breakthrough status.
Liquidia Gets Bullish Signal from Hikma vs Amarin Ruling
Raymond James reiterates Strong Buy rating and $68 target on Liquidia after the Supreme Court’s positive Hikma v. Amarin decision.
Enobosarm Grabs Novo Nordisk’s Attention: Veru’s Big Obesity Breakthrough
Veru partnered with Novo Nordisk to test enobosarm + Wegovy for fat loss while keeping muscle; stock surged.